Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00806221 · ClinicalTrials.gov registry record · Phase 2
An Open-Label Study Investigating the Effects of Early Skin Barrier Protection on the Development of Atopic Dermatitis
A Phase 2 study of Atopic Dermatitis, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT00806221 is a Phase 2 study of Atopic Dermatitis that has completed, run by Oregon Health and Science University. The registered enrollment target is 22 participants, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00806221, a Phase 2 study of Atopic Dermatitis, has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether early use of a bland emollient in newborns, prior to the clinical signs of skin disease, will delay the onset or prevent the development of atopic dermatitis.
Conditions Studied
Interventions
- DRUG emollient (Cetaphil cream)
Study Locations (1)
Oregon
- Oregon Health & Science University, Department of Dermatology - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2006-11 |
| Est. Completion | 2009-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00806221
The ClinicalTrials.gov registry entry for NCT00806221 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (96% lower). The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 1 intervention - of which emollient (Cetaphil cream) is the first listed.
NCT00806221 reports 1 study location spanning 1 distinct geographic area - top geographies include Oregon.
Frequently Asked Questions
What is clinical trial NCT00806221 about?
NCT00806221 is a clinical study titled "An Open-Label Study Investigating the Effects of Early Skin Barrier Protection on the Development of Atopic Dermatitis". The purpose of this study is to determine whether early use of a bland emollient in newborns, prior to the clinical signs of skin disease, will delay the onset or prevent the development of atopic dermatitis.
What is the current status of trial NCT00806221?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2006-11. Estimated completion is 2009-11.
What conditions does trial NCT00806221 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT00806221?
The interventions under investigation include: emollient (Cetaphil cream) (DRUG).
Who is sponsoring clinical trial NCT00806221?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00806221 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Cardamom and Topical Roseomonas in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
A Study Evaluating TRIV-509 in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.